• Cancel
    Date：2022-05
    http://www.ceccapitalgroup.com/index.php?a=shows&catid=34&id=731

    Senlang Biotechnology announced the successful closing of RMB 200 million from Qianhai Ark Asset Management. CEC Capital Group acted as the exclusive financial advisor for Senlang Biotechnology in this transaction.

  • Cancel
    Date：2022-05

    Exclusive Financial Advisor to DOBOSO

  • Cancel
    Date：2022-04
    http://www.ceccapitalgroup.com/index.php?a=shows&catid=34&id=732

    Fosun Pharmaceutical recently announced that its subsidiary, YanengBIO, along with its existing shareholders, has entered into a relevant agreement with Yaneng Bioscience under CBridge Capital. Upon completion of the transaction, YanengBIO will transition

  • Cancel
    Date：2022-02

    Exclusive Financial Advisor to DECANS

  • Cancel
    Date：2022-02

    Exclusive Financial Advisor to Unionstrong

  • Cancel
    Date：2022-01

    Exclusive Financial Advisor to Vibrant Therapeutics

  • Cancel
    Date：2022-01

    Financial Advisor to PAG

  • Cancel
    Date：2022-01
    http://www.ceccapitalgroup.com/index.php?a=shows&catid=34&id=717

    Accro Bioscience (Suzhou) Limited, a leader in China's small molecule drug development, recently closed its Series B fundraising, raising over $50 million and surpassing its initial fundraising target. The round was led by Hongtai Aplus, with participatio

  • Cancel
    Date：2021-12
    http://www.ceccapitalgroup.com/index.php?a=shows&catid=34&id=791

    ChosenMed successfully closed a Series C2 financing, raising several hundred million RMB from YiJing Capital, with participation from Linzhuo Industry Fund and other leading institutions. CEC Capital Group served as the exclusive financial advisor in